Adocia Logo

Adocia

Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.

ADOC | PA

Overview

Corporate Details

ISIN(s):
FR0011184241 (+1 more)
LEI:
969500ZL79KYH9PTYP78
Country:
France
Address:
115 AVENUE LACASSAGNE, 69003 LYON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Adocia is a clinical-stage biotechnology company founded in 2005, specializing in the development of innovative treatments for metabolic diseases, primarily diabetes and obesity. The company's core focus is on creating novel formulations of already-approved therapeutic proteins, peptides, and hormones, such as insulin, to improve their performance. Its diverse pipeline targets type 1 and type 2 diabetes and obesity. Additionally, Adocia develops platforms for cell therapies, including immunoprotective scaffolds. The company's business model is to develop products and technologies to the human proof-of-concept stage before licensing them to commercial partners.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-02 10:34
Major Shareholding Notification
Déclaration d'intention (FS 225C1435)
French 130.2 KB
2025-09-02 10:30
Major Shareholding Notification
Franchissement de seuil
French 111.8 KB
2025-07-11 11:18
Major Shareholding Notification
Franchissements de seuil
French 116.2 KB
2025-06-12 18:00
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
English 492.1 KB
2025-06-12 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 491.7 KB
2025-05-22 18:00
Regulatory News Service
Inside Information / Other news releases
English 452.1 KB
2025-05-22 18:00
Regulatory News Service
Informations privilégiées / Autres communiqués
French 472.2 KB
2025-05-21 18:00
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 120.9 KB
2025-05-21 18:00
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 130.5 KB
2025-05-15 18:00
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
English 474.1 KB
2025-05-15 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 473.1 KB
2025-05-14 18:00
Earnings Release
Inside Information / News release on accounts, results
English 576.9 KB
2025-05-14 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 531.5 KB
2025-04-30 18:00
Registration Form
Inside Information / Other news releases
English 473.1 KB
2025-04-30 18:00
Registration Form
Informations privilégiées / Autres communiqués
French 461.0 KB

Automate Your Workflow. Get a real-time feed of all Adocia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Adocia

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Adocia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-03-21 N/A Other Buy 51,921 499,999.23 EUR
2024-03-21 N/A Other Buy 15,576 149,996.88 EUR
2023-12-29 N/A Other Sell 20,000 236,550.00 EUR
2023-10-05 N/A Other Sell 50,000 400,000.00 EUR
2023-09-20 N/A Other Sell 36,240 291,376.85 EUR
2023-07-28 N/A Other Buy 220,264 999,998.56 EUR
2023-07-28 N/A Other Buy 110 499.40 EUR

Peer Companies

Company Country Ticker View
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.